Stockholm - November 15, 2024 - Inify Laboratories AB (publ), a unique
laboratory service provider within pathology and cancer diagnostics, hereby
invites its shareholders to Extraordinary General Meeting on December 6, 2024.

Please find attached the invitation including attachment, agenda and details on
how to register and vote. The invitation is also available on the company's
website: www.inify.com.

For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann
-charlotte.linderoth@inify.com or: ir@inify.com.

###

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI-
supported workflow to optimize quality and response times, initially within
prostate.The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off
fromContextVision (https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. It is listed onEuronext Growth
Oslo under the ticker INIFY.

###

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.